Rocheの実験的な 肥満剤 CT-388は 体重を著しく減量し、血糖を改善しました。 Roche's experimental obesity drug CT-388 caused significant weight loss and improved blood sugar in Phase 2 trials.

Rocheは,実験的な 肥満薬 CT-388の検査結果について報告している GLP-1とGIP受容体の両方を 毎週注射できる Roche has reported positive Phase 2 trial results for its experimental obesity drug CT-388, a weekly injectable targeting both GLP-1 and GIP receptors. 48週後,最高用量 (24 mg) は,プラセボ調整した体重減少率を平均22. 5%で,その87%は少なくとも10%,47. 8%は20%以上, 26. 1%は30%以上で減少させた. After 48 weeks, the highest dose (24 mg) led to an average 22.5% placebo-adjusted weight loss, with 87% losing at least 10%, 47.8% over 20%, and 26.1% more than 30%. 前糖尿病の参加者のうち、73%が正常な血糖値に達し、プラセボ群では7.5%でした。 Among pre-diabetic participants, 73% achieved normal blood glucose levels, compared to 7.5% in the placebo group. 薬は一般的によく耐えるもので,軽度から中度までの胃腸の副作用と,薬の中止率は低い. The drug was generally well-tolerated, with mild to moderate gastrointestinal side effects and low discontinuation rates. RocheはCT-388をフェーズ3に推進し,代謝疾患の治療の特例を拡大し続けている. Roche plans to advance CT-388 into Phase 3 trials and continues expanding its portfolio of metabolic disease treatments.